AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39088470 — intervention group
Group type: COMPARATOR
Intervention: Passive Choice (PC) control group
Number of subjects: 743
Study 39088510 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured supervised exercise training
Number of subjects: 150
Study 39088510 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational counselling on physical activity (PA)
Number of subjects: 150
Study 39088510 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 39088510 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of daily steps
Number of subjects: 150
Study 39088510 — intervention group
Group type: EXPERIMENTAL
Intervention: Active kilocalories during pregnancy
Number of subjects: 150
Study 39088510 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity physical activity (MVPA)
Number of subjects: 150
Study 39088766 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led two-session intervention (focused on breathing techniques, postural positions, and fan therapy)
Number of subjects: 247
Study 39088766 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 247
Study 39088774 — intervention group
Group type: EXPERIMENTAL
Intervention: Devimistat (CPI-613) plus modified FFX (mFFX)
Number of subjects: 528
Study 39088774 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose FFX
Number of subjects: 528
Study 39088774 — intervention group
Group type: EXPERIMENTAL
Intervention: Devimistat plus mFFX
Number of subjects: 528
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg once daily (cohort A)
Number of subjects: 466
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 75-100 mg once daily (cohort B)
Number of subjects: 466
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg once daily (cohort A) with brain metastasis
Number of subjects: 466
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg once daily (cohort A) without brain metastasis
Number of subjects: 466
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 75-100 mg once daily (cohort B) with brain metastasis
Number of subjects: 466
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib 75-100 mg once daily (cohort B) without brain metastasis
Number of subjects: 466
Study 39089004 — intervention group
Group type: EXPERIMENTAL
Intervention: Befotertinib (both cohorts)
Number of subjects: 466
Study 39089011 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Number of subjects: 0
Study 39089011 — intervention group
Group type: COMPARATOR
Intervention: Contemporary conventional cardiopulmonary bypass (cCPB)
Number of subjects: 0
Study 39089109 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital biomarkers based on sensor data from a wrist-worn wearable, including heart rate variability and skin conductance levels, combined with deep-learning features from a self-supervised convolutional autoencoder.
Number of subjects: 0
Study 39089299 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative PPP nomogram
Number of subjects: 2414
Study 39089299 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual PPP nomogram
Number of subjects: 2414
Study 39089305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib plus osimertinib (oral tepotinib 500 mg plus oral osimertinib 80 mg once daily)
Number of subjects: 128
Study 39089305 — intervention group
Group type: EXPERIMENTAL
Intervention: Tepotinib plus osimertinib
Number of subjects: 128
Study 39089326 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive imagery instructions
Number of subjects: 26
Study 39089326 — intervention group
Group type: COMPARATOR
Intervention: Neutral imagery instructions
Number of subjects: 26
Study 39089519 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg once-daily
Number of subjects: 274
Study 39089519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 39089517 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic resection (ER) of LNPCPs
Number of subjects: 2956
Study 39089517 — intervention group
Group type: COMPARATOR
Intervention: Direct surgery for LNPCPs
Number of subjects: 2956
Study 39089633 — intervention group
Group type: EXPERIMENTAL
Intervention: STRIDE
Number of subjects: 479
Study 39089633 — intervention group
Group type: EXPERIMENTAL
Intervention: durvalumab
Number of subjects: 479
Study 39089633 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 479
Study 39089652 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 over 60 days
Number of subjects: 92
Study 39089652 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic preparation
Number of subjects: 92
Study 39089652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 39089718 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to protein signature with top-down treatment algorithm (anti-tumour necrosis factor agent with/without an immunomodulator)
Number of subjects: 0
Study 39089718 — intervention group
Group type: COMPARATOR
Intervention: Clinical management based on stepwise escalation of treatment after failure of first-line treatment
Number of subjects: 0
Study 39089896 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education (intensive follow-up schedule of phone calls, home visits, text messages, plus cardiologist visits)
Number of subjects: 0
Study 39089896 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard appointments with cardiologist and general practitioner)
Number of subjects: 0
Study 39089896 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Number of subjects: 0
Study 39089896 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39089900 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 126
Study 39089900 — intervention group
Group type: COMPARATOR
Intervention: Virtual Reality
Number of subjects: 126
Study 39089900 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 126
Study 39090192 — intervention group
Group type: EXPERIMENTAL
Intervention: ADE-RS5 (5-gene-drug resistance score)
Number of subjects: 163
Study 39090192 — intervention group
Group type: EXPERIMENTAL
Intervention: pLSC6 (leukemic-stemness signature)
Number of subjects: 163
Study 39090192 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-4 (high-scores for ADE-RS5 and pLSC6)
Number of subjects: 163
Study 39090192 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-2/3 (one high and one low-score)
Number of subjects: 163
Study 39090192 — intervention group
Group type: COMPARATOR
Intervention: Group 2 vs. Group 1
Number of subjects: 163
Study 39090192 — intervention group
Group type: COMPARATOR
Intervention: Group 3 vs. Group 1
Number of subjects: 163
Study 39090192 — intervention group
Group type: COMPARATOR
Intervention: Group 4 vs. Group 1
Number of subjects: 163
Study 39090218 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-delivered resistance exercise intervention (n=28)
Number of subjects: 52
Study 39090218 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact control (MCC) (n=24)
Number of subjects: 52
Study 39090323 — intervention group
Group type: EXPERIMENTAL
Intervention: N-L-NMMA at 250 μg/kg per minute combined with trimethaphan at 4 mg/min
Number of subjects: 10
Study 39090323 — intervention group
Group type: COMPARATOR
Intervention: Control group (White women)
Number of subjects: 10
Study 39090517 — intervention group
Group type: EXPERIMENTAL
Intervention: PFMT combined with Otago exercises
Number of subjects: 43
Study 39090517 — intervention group
Group type: COMPARATOR
Intervention: PFMT alone
Number of subjects: 43
Study 39090589 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) visits
Number of subjects: 11030
Study 39090589 — intervention group
Group type: COMPARATOR
Intervention: Health facility/pharmacy visits
Number of subjects: 11030
Study 39090589 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported malaria treatment
Number of subjects: 11030
Study 39090589 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported malaria treatment among febrile individuals
Number of subjects: 11030
Study 39090589 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with healthcare seeking
Number of subjects: 11030
Study 39090600 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) plus bile duct stenting
Number of subjects: 120
Study 39090600 — intervention group
Group type: COMPARATOR
Intervention: Bile duct stenting alone
Number of subjects: 120
Study 39090664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor intervention based on immersive virtual reality (VR)
Number of subjects: 34
Study 39090664 — intervention group
Group type: COMPARATOR
Intervention: Traditional cognitive training
Number of subjects: 34
Study 39090770 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic single-anastomosis side-to-side duodeno-ileostomy (MagDI) using the novel linear magnetic anastomosis system (LMAS [3 cm])
Number of subjects: 24
Study 39090770 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic single-anastomosis side-to-side duodeno-ileostomy (MagDI)
Number of subjects: 24
Study 39091032 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-person self-talk
Number of subjects: 0
Study 39091032 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39091122 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted health dialogues (THDs)
Number of subjects: 1831
Study 39091324 — intervention group
Group type: EXPERIMENTAL
Intervention: efmoroctocog alfa prophylaxis
Number of subjects: 189
Study 39091353 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild anemia
Number of subjects: 1071
Study 39091353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe anemia
Number of subjects: 1071
Study 39091353 — intervention group
Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 1071
Study 39091353 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (overall)
Number of subjects: 1071
Study 39091509 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS tool with behavioral nudges
Number of subjects: 1527
Study 39091509 — intervention group
Group type: COMPARATOR
Intervention: CDS tool without behavioral nudges (control)
Number of subjects: 1527
Study 39091606 — intervention group
Group type: EXPERIMENTAL
Intervention: Gumarontinib
Number of subjects: 32
Study 39091640 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased levels of interleukin 9
Number of subjects: 452
Study 39091640 — intervention group
Group type: COMPARATOR
Intervention: Disease-free controls
Number of subjects: 452
Study 39091670 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycytidine/deoxythymidine (dC/dT) combination therapy
Number of subjects: 10
Study 39091669 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (Allisartan starting at 80 mg/day, increased to 160 mg/day at month 2, combined with amlodipine 2.5 mg/day at month 4 if BP remained uncontrolled)
Number of subjects: 320
Study 39091669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 39091672 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutimlimab
Number of subjects: 39
Study 39091672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Part A)
Number of subjects: 39
Study 39091673 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose mRNA-1273 100 μg
Number of subjects: 2490
Study 39091673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of mRNA-1273 50 μg
Number of subjects: 2490
Study 39091673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2490
Study 39091678 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevase® enzyme blend
Number of subjects: 0
Study 39091678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39092032 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fasting (Group-A)
Number of subjects: 120
Study 39092032 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fasting (Group-B)
Number of subjects: 120
Study 39093227 — intervention group
Group type: EXPERIMENTAL
Intervention: cGMP-manufactured WJMSCs
Number of subjects: 0
Study 39093262 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg sodium (284 mg inclisiran)
Number of subjects: 2975
Study 39093262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2975
Study 39093380 — intervention group
Group type: EXPERIMENTAL
Intervention: NSPIT plus 500 mg of oral systemic metronidazole three times a day for 7 days
Number of subjects: 21
Study 39093380 — intervention group
Group type: COMPARATOR
Intervention: NSPIT plus placebo
Number of subjects: 21
Study 39093385 — intervention group
Group type: EXPERIMENTAL
Intervention: Latero-lateral duodeno-ileostomy + Sleeve Gastrectomy with Magnet Anastomosis System
Number of subjects: 0
Study 39093385 — intervention group
Group type: COMPARATOR
Intervention: Standard SADI-S
Number of subjects: 0
Study 39093566 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (12-minute video with 4 Spanish-language stories)
Number of subjects: 451
Study 39093566 — intervention group
Group type: COMPARATOR
Intervention: Printed, culturally tailored T2D education materials (control group)
Number of subjects: 451
Study 39093566 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention
Number of subjects: 451
Study 39093639 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support
Number of subjects: 1393
Study 39093639 — intervention group
Group type: COMPARATOR
Intervention: Usual PICU care
Number of subjects: 1393
Study 39093661 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at weeks 0 and 4, then every 12 weeks through week 52
Number of subjects: 55
Study 39093662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrafol Women's Vegan Capsules, Nutraceutical Wellness, Inc.
Number of subjects: 95
Study 39093916 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Number of subjects: 50
Study 39093916 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 50
Study 39093981 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet regimen of chidamide, decitabine, and anti-PD-1 camrelizumab (CDP)
Number of subjects: 52
Study 39094065 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 0
Study 39094065 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39094377 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made insoles adapted to flip-flops
Number of subjects: 80
Study 39094432 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-0001 (up to 30 g twice a day)
Number of subjects: 81
Study 39094432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 39094560 — intervention group
Group type: EXPERIMENTAL
Intervention: NACRT and PD-1 antibody sintilimab
Number of subjects: 134
Study 39094560 — intervention group
Group type: COMPARATOR
Intervention: NACRT
Number of subjects: 134
Study 39094630 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 1468
Study 39094677 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 250 mg
Number of subjects: 137
Study 39094677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 39094733 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium score (CACS) ≥ median
Number of subjects: 2791
Study 39094733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of the pulmonary artery to aorta diameters (PA:A ratio) ≥ 1
Number of subjects: 2791
Study 39094733 — intervention group
Group type: EXPERIMENTAL
Intervention: CACS/CVD in NEPD vs EPD
Number of subjects: 2791
Study 39094733 — intervention group
Group type: EXPERIMENTAL
Intervention: PA:A ratio/COPD exacerbation in NEPD vs EPD
Number of subjects: 2791
Study 39094734 — intervention group
Group type: EXPERIMENTAL
Intervention: SWI-/SNF-deficient undifferentiated carcinomas
Number of subjects: 59
Study 39094743 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN-α-2a treatment for 48 weeks
Number of subjects: 180
Study 39094743 — intervention group
Group type: COMPARATOR
Intervention: NUC cessation
Number of subjects: 180
Study 39095086 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-assisted coiling (BAC)
Number of subjects: 233
Study 39095086 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-assisted coiling (SAC)
Number of subjects: 233
Study 39095086 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow diversion (FD)
Number of subjects: 233
Study 39095086 — intervention group
Group type: COMPARATOR
Intervention: Coiling alone
Number of subjects: 233
Study 39095206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular senescence group
Number of subjects: 0
Study 39095206 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 39095206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rat models with vascular senescence
Number of subjects: 0
Study 39095502 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline NPCs ratio (≥5%)
Number of subjects: 1363
Study 39095502 — intervention group
Group type: EXPERIMENTAL
Intervention: High residual NPCs ratio at diagnosis or relapse
Number of subjects: 1363
Study 39095502 — intervention group
Group type: EXPERIMENTAL
Intervention: High absolute percentages of NPCs at undetectable MRD
Number of subjects: 1363
Study 39095502 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouping based on NPCs ratio at MRD-positive phases (<50%, 50-90%, ≥90%)
Number of subjects: 1363
Study 39095502 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic MRD model based on NPCs ratio trend
Number of subjects: 1363
Study 39095524 — intervention group
Group type: EXPERIMENTAL
Intervention: Room Air (RA) challenge
Number of subjects: 1022
Study 39095560 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsidian RFT
Number of subjects: 15
Study 39095571 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Health (BH) care management including cognitive behavioral therapy, medication adjustments, and case management
Number of subjects: 632
Study 39095571 — intervention group
Group type: COMPARATOR
Intervention: Electronic Medical Record Clinical Decision Support (EMR-CDS)
Number of subjects: 632
Study 39095597 — intervention group
Group type: EXPERIMENTAL
Intervention: L. major-infected Phlebotomus duboscqi
Number of subjects: 14
Study 39095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic biopsy
Number of subjects: 14
Study 39095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 14
Study 39095597 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at >12 months
Number of subjects: 14
Study 39095724 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple resistance training (SRA)
Number of subjects: 17
Study 39095735 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised structured exercise intervention emphasizing increasing and varied intensities of aerobic and resistance exercise
Number of subjects: 12
Study 39095735 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised structured exercise intervention
Number of subjects: 12
Study 39095759 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography-guided pancreatic arterial infusion (PAI) of GEMOX chemotherapy
Number of subjects: 51
Study 39095759 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (IVC) of GEMOX
Number of subjects: 51
Study 39095808 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP quartiles
Number of subjects: 685
Study 39095818 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone lid technique using a piezoelectric device
Number of subjects: 24
Study 39095818 — intervention group
Group type: COMPARATOR
Intervention: Traditional method using rotatory burs
Number of subjects: 24
Study 39095860 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics after GA
Number of subjects: 58
Study 39095860 — intervention group
Group type: COMPARATOR
Intervention: No probiotics after GA
Number of subjects: 58
Study 39095863 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention
Number of subjects: 720
Study 39095863 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention (completed six sessions)
Number of subjects: 720
Study 39095863 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Mother-Healthy Baby (HMHB) intervention (for women with mild anxiety)
Number of subjects: 720
Study 39095866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab (10 mg daily) with therapeutic plasma exchange (TPE) and immunosuppression for 30 days post-TPE
Number of subjects: 19
Study 39095866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caplacizumab with TPE and immunosuppression
Number of subjects: 19
Study 39095866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab administered to patients with inhibitor boosting (88.9%) after TPE completion
Number of subjects: 19
Study 39095866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab administered to patients without inhibitor boosting prior to TPE completion
Number of subjects: 19
Study 39095876 — intervention group
Group type: EXPERIMENTAL
Intervention: Online membership-based fitness program (8-week duration, includes 16 pre-recorded videos and 9 live exercise classes)
Number of subjects: 31
Study 39095876 — intervention group
Group type: EXPERIMENTAL
Intervention: Online membership-based fitness program
Number of subjects: 31
Study 39095884 — intervention group
Group type: COMPARATOR
Intervention: rs-fMRI activity in resuscitated patients
Number of subjects: 31
Study 39095919 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1500 mg)
Number of subjects: 95
Study 39095919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 39095923 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimdia's pdSTIM System (phrenic nerve stimulation)
Number of subjects: 0
Study 39095923 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 0
Study 39096236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reserve
Number of subjects: 404